Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tairilafon
- Development stage
- Phase 1
- Lead developer
- Nanjing Zhongrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tairilafon is a small molecule free radical scavenger developed by Nanjing Zhongrui Pharmaceutical for the treatment of acute cerebral infarction (ischemic stroke). It is a derivative of edaravone, designed to improve the pharmacological profile of the parent compound. Tairilafon works by scavenging reactive oxygen species (ROS) and inhibiting lipid peroxidation, thereby protecting neuronal cells from oxidative stress and apoptosis during the reperfusion phase following an ischemic event. The drug is formulated for intravenous administration and has been investigated in Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.
- Other names
- 泰瑞拉奉Edaravone phosphate
Beyond the preview
Go deeper on tairilafon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tairilafon.